KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $25.6 million.

  • Aquestive Therapeutics' Total Current Liabilities rose 6878.3% to $25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 6878.3%. This contributed to the annual value of $18.9 million for FY2024, which is 304.24% up from last year.
  • Aquestive Therapeutics' Total Current Liabilities amounted to $25.6 million in Q3 2025, which was up 6878.3% from $23.2 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Total Current Liabilities peaked at $40.4 million during Q1 2023, and registered a low of $13.9 million during Q2 2024.
  • Over the past 5 years, Aquestive Therapeutics' median Total Current Liabilities value was $23.2 million (recorded in 2025), while the average stood at $25.0 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Total Current Liabilities skyrocketed by 7996.72% in 2022, and later tumbled by 6405.19% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Total Current Liabilities (Quarter) stood at $22.0 million in 2021, then soared by 79.97% to $39.5 million in 2022, then crashed by 53.68% to $18.3 million in 2023, then grew by 3.04% to $18.9 million in 2024, then surged by 35.56% to $25.6 million in 2025.
  • Its Total Current Liabilities was $25.6 million in Q3 2025, compared to $23.2 million in Q2 2025 and $18.3 million in Q1 2025.